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Gheath Alatrash, Matteo Pelosini, Rima M. Saliba, Ebru Koca, Gabriela Rondon,
Borje S. Andersson, Alexandre Chiattone, Weiqing Zhang, Sergio A. Giralt,
Amanda M. Cernosek, Partow Kebriaei, Amin M. Alousi, Uday R. Popat, Chitra Hosing,
Issa F. Khouri, Richard E. Champlin, Marcos J. de LimaComplete remission (CR) is the gold standard for assessing outcomes following chemotherapy for acute
myelogenous leukemia (AML). ‘‘CRp,’’ a response criterion defined as fulfillment of all criteria for CR except
platelet count recovery to$100 109/L, is associated with inferior outcomes following chemotherapy. The
prognostic importance of CRp before allogeneic stem cell transplantation (allo-SCT) remains unknown. We
analyzed a cohort of AML (n5 334) and myelodysplastic syndrome (MDS; n5 10) patients to determine the
prognostic significance of achieving CR versus CRp before allo-SCT. At time of transplantation, 266 patients
were in CR (CR1 and $CR2) and 78 in CRp (CR1p and $CR2p). Median follow-up was 38 months (3-131
months). Overall survival, progression-free survival, and nonrelapse mortality (NRM) were most favorable in
patients transplanted in CR (CR1 or$CR2) compared with CRp (CR1p or$CR2p). Achieving CR is there-
fore associated with improved posttransplantation outcomes compared with achieving CRp and is a
significant prognostic factor that needs to be considered when evaluating AML/MDS patients for clinical trials
and allo-SCT.
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Allogeneic hematopoietic stem cell transplanta-
tion (allo-SCT) is a potentially curative option for
patients with acute myelogenous leukemia (AML)
and myelodysplastic syndrome (MDS). However,
the optimal candidates for allo-SCT and the ideal
timing of the transplantation have not been agreed
upon universally Numerous prognostic factorsDepartment of Stem Cell Transplantation and Cellular
py, TheUniversity of TexasM.D. Anderson Cancer Cen-
ouston, Texas.
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6/j.bbmt.2011.05.018can help identify patients who are at a high risk
for relapse and patients who will benefit most from
allo-SCT [1,2]. For example, pre- and postinduction
therapy characteristics have been shown to correlate
with relapse and mortality outcomes. Although
pretherapy characteristics, primarily cytogenetic
abnormalities and genetic mutations, are often used for
patient selection, data obtained during and after
induction chemotherapy have also been shown to
provide valuable prognostic information. In 1 study,
patients who required more chemotherapy courses to
achieve complete remission (CR) were shown to have
a shorterdisease-free interval thanpatientswho required
fewer treatment courses [3]. The prognostic value of
peripheral blood (PB) parameters, specifically platelet
count, in the setting of allo-SCT remains unknown.
Many patients achieve a morphologic complete re-
mission, clearing the bone marrow (BM) of detectable
leukemia cells, but have incomplete recovery of hema-
topoiesis. Achieving disease remission without platelet
recovery (ie, PB platelets \100  109 platelets/L),
frequently referred to as CRp (or CRi), is reported as1841
1842 Biol Blood Marrow Transplant 17:1841-1845, 2011G. Alatrash et al.a form of partial remission in patients receiving induc-
tion chemotherapy and is correlated with inferior
disease outcomes compared with patients who achieve
hematologic recovery [4-7]. Whether or not outcomes
following allo-SCT are adversely affected in patients
with CRp is yet to be defined. Here, we describe a ret-
rospective analysis we conducted to assess the prog-
nostic significance of achieving CR (vs CRp) at the
time of allo-SCT.MATERIALS AND METHODS
Patient Selection
The study cohort comprised 344 patients with
AML (n 5 334) or high-risk MDS (n 5 10) trans-
planted at The University of Texas M.D. Anderson
Cancer Center between July 1995 and December
2007. Patients were categorized as CR
(ie, \5% BM blasts and $100  109 platelets/L of
PB following chemotherapy) or CRp (ie, \5% BM
blasts but no platelet recovery at time of allo-SCT,
which was at least 28 days after chemotherapy). We
classified patients as first CR or CRp based on re-
sponse following induction chemotherapy or equal to
or greater than second CR ($CR2) or CRp
($CR2p) based on response following salvage chemo-
therapy. A minimum of 28 days from the last chemo-
therapy to the start of the preparative regimens had
elapsed before the patients were assigned to the afore-
mentioned disease status categories. All protocols, in-
cluding this retrospective analysis, were approved by
the institutional review board of the M.D. Anderson
Cancer Center. Patients provided written informed
consent for their treatment. Patients were treated in
accordance with the Declaration of Helsinki.
Preparative regimens were classified as myeloabla-
tive (n5 233) or reduced-intensity conditioning (RIC)
(n5 111). The myeloablative regimens were primarily
busulfan-based, including oral and intravenous (i.v.)
busulfan (50%; n 5 173), or total body irradiation
(TBI) based (2%; n5 7). The RIC regimens primarily
included fludarabine and melphalan (21%; n 5 73) or
were busulfan based (6%; n5 21). Sixty-one percent of
patients had received matched-sibling donor trans-
plants (n5 208), and 34% (n5 117) received matched
unrelated donor transplants. Patients received a tacro-
limus-based regimen (n 5 341), a cyclosporine-based
regimen (n 5 1), or methotrexate alone (n 5 1) for
graft-versus-host disease (GVHD) prophylaxis. One
patient received a syngeneic stem cell transplantation
(SCT) and did not receive GVHD prophylaxis. An-
tithymocyte globulin (ATG)was administered to those
who received grafts from unrelated donors.
Cytogenetic risk categories were defined as follows:
good-risk cytogenetics included patients with tran-
slocation (t)(8;21); inversion (inv)(16), or t(16;16);deletion (del)(9q); or t(15;17). Intermediate-risk cytoge-
netics included patients with a normal karyotype; 2Y;
del (5q); loss of 7q; t(9;11); 111; del(11q); abnormality
(12p);113; del(20q); or121. Poor-risk cytogenetics in-
cluded patients with a complex karyotype ($3 abnor-
malities); inv(3) or t(3;3); t(6;9); t(6;11); 27; 18 (sole
abnormality); or 18 with 1 other abnormality other
than t(8;21), t(9;11), inv(16), or t(16;16); t(11;19)
(q23;p13.1) [8].
Statistical Analysis
The primary outcome measures were overall sur-
vival (OS), progression-free survival (PFS), and nonre-
lapse mortality (NRM). All outcomes were evaluated
from the transplantation date. PFS was defined as the
time to disease progression or death. Actuarial OS
and PFS times were estimated using the Kaplan-
Meier method [9]. We estimated cumulative NRM in-
cidence considering disease progression and death in
relapse or with persistent disease as competing risks.
We used the Cox proportional hazards model to evalu-
ate prognostic factors for OS, PFS, and NRM. Prog-
nostic factors considered included disease status at
the time of allo-SCT, patient age, patient gender, do-
nor type, stem cell source, cytogenetics, and condition-
ing regimen. Statistical significance was defined at the
0.05 level. All the statistical analyses were performed
using Stata version 9.0 software (StataCorp. 2005, Col-
lege Station, TX).RESULTS
Patient Characteristics
Patient characteristics are presented in Table 1.
The median age was 49 years (range: 6-73) and 54%
were male (n 5 186). The median time from the end
of chemotherapy to allo-SCT was 66 days (range:
29-303). Disease status at SCT was CR1 in 48% of pa-
tients (n 5 164), $CR2 in 30% (n 5 102), CR1p in
14% (n 5 48), and $CR2p in 9% (n 5 30). Of the
10 patients with MDS, 6 patients were in CRp. Cyto-
genetic data were available for 92% (n 5 315) of pa-
tients. The AML subtypes, according to World
Health Organization classification, included M0-M2
(n 5 136), M3 (n 5 4), M4-M5 (n 5 91), M6-M7 (n
5 17), and unclassified (n 5 96). The distribution of
cytogenetics according to disease status is shown in
Table 2. The proportion of patients with poor-risk cy-
togenetics was comparable between the CR and CRp
patients, 37% and 31% (P 5 .30), respectively. The
proportion of patients with poor-risk cytogenetics
was also comparable within each subgroup, CR1
(38%) versus CR1p (42%) (P 5 .50) and $CR2
(13%) versus $CR2p (20%) (P 5 .20). The source of
stem cells was BM in 40% of patients (n 5 137) and
PB in 60% (n 5 207). The median times to
Table 1. Patient Characteristics
Number (%)
Gender
Male 186 (54)
Female 158 (46)
Age (years)
>50 163 (47)
#50 181 (53)
Disease status at transplantation
CR1 164 (48)
$CR2 102 (30)
CR1p 48 (14)
$CR2p 30 (9)
Cytogenetics
Good 20 (6)
Intermediate 194 (56)
Poor 101 (29)
Unknown 29 (8)
Donor type
Matched sibling 208 (61)
MUD 117 (34)
1 Ag MM related 14 (4)
1 Ag MM unrelated 5 (1)
Stem cell source
Bone marrow 137 (40)
Peripheral blood 207 (60)
Number of prior chemotherapy
courses
#2 125 (36)
>2 209 (61)
Unknown 10 (3)
CR1 indicates first complete remission; $CR2, equal to or more than
second complete remission; CR1p, CR1 without platelet recovery;
$CR2p, equal to or more than CR2 without platelet recovery; MUD,
matched unrelated donor; MM, mismatched.
Table 3. Impact of Platelet Recovery on Overall Survival,
Progression-Free Survival, and Nonrelapse Mortality for All
Patients, CR1 Patients, and $CR2 Patients at Time of Stem
Cell Transplantation
Patient Group
OS
HR (P value)
PFS
HR (P value)
NRM
HR (P value)
CRp versus CR 2 (P < .001) 1.7 (P5 .001) 1.7 (P 5 .03)
CR1p versus CR1 2.1 (P 5 .002) 1.7 (P 5 .02) 2.3 (P 5 .01)
$CR2p versus $CR2 1.9 (P 5 .02) 1.7 (P 5 .05) 1.1 (P 5 .9)
OS indicates overall survival; PFS, progression-free survival; NRM, non-
relapse mortality; HR, hazards ratio; CRp, remission without platelet
recovery; CR, complete remission; CR1p, CR1 without platelet recov-
ery; CR1, first complete remission; $CR2p, equal to or greater than
second complete remission without platelet recovery; $CR2, equal
to or greater than second complete remission. Outcomes are compared
at the median follow-up time: 36 months for the CR versus CRp and
CR1 versus CR1p groups, and at 60 months for the $CR2 versus
$CR2p groups.
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and 89 days, respectively. Successful engraftment was
seen in 98% of patients.Prognostic Factors for OS and PFS
After a median follow-up of 38 months in surviv-
ing patients (range: 3-131 months), a total of 153
deaths occurred in this cohort. The actuarial overall
survival was 57% (95% confidence interval [CI]
51-62) and PFS 50% (95% CI 44-55) at 36 months
posttransplantation. Almost one-third of the patients
(n 5 95) experienced disease progression. In univar-
iate analysis, disease status at time of SCT was the
only significant predictor of OS and PFS (Table 3).Table 2. Distribution of Cytogenetics and Age According to
Response Group
Patient parameter
CR1
n 5 164
CR1p
n 5 48
$CR2
n 5 102
$CR2p
n 5 30
Cytogenetics
Good 1% 2% 17% 3%
Intermediate 57% 50% 57% 60%
Poor 38% 42% 13% 20%
Unknown 4% 6% 14% 17%
Age (years) >50 47% 71% 34% 57%
CR1 indicates first complete remission; CR1p, CR1 without platelet re-
covery; $CR2, equal to or greater than second complete remission;
$CR2p, equal to or greater than CR2 without platelet recovery.Compared with patients in CR, patients in CRp
had significantly worse OS (39% vs 62%, P\ .001)
and PFS (36% vs 54%, P 5 .001) at 36 months post-
transplantation (Table 3). None of the additional fac-
tors evaluated were shown to be significant predictors
of OS, or PFS including gender, age (.50 vs #50
years), graft type (matched related versus other), graft
source (peripheral blood vs bone marrow), prepara-
tive regimen (RIC vs myeloablative), and cytogenetics
(poor risk vs good/intermediate risk).
Subgroup analyses evaluating the impact of plate-
let recovery separately in CR1 and $CR2 patients
showed consistent results. At 36 months, OS was
higher for patients receiving transplants while in
CR1 (64%) compared with those receiving transplants
in CR1p (45%) (hazard ratio [HR] 5 2.1; P 5 .002)
(Tables 3 and 4 and Figure 1A). PFS was also higher
for patients receiving transplants in CR1 (54%) com-
pared with those receiving transplants in CR1p
(38%) (HR5 1.7; P5 .02) (Tables 3 and 4, Figure 1B).
Similar results were found in patients who received
stem cell transplants while in $CR2 or $CR2p. At
a median follow-up of 60 months (range: 5-130
months), OS was higher for patients receiving trans-
plants while in $CR2 (53%) compared with those
receiving transplants in $CR2p (31%) (HR 5 1.9;
P 5 .02) (Table 4 and Figure 1A). PFS at 60 months
was also higher for patients receiving transplants inTable 4. 36-Month Outcomes by Pretransplantation Disease
Status
Pretransplant Disease Status OS (95% CI) PFS (95% CI) NRM (95% CI)
CR1 (n 5 164) 64% (56-72) 54% (45-61) 18% (12-25)
$CR2 (n 5 102) 58% (47-67) 54% (44-63) 27% (19-38)
CR1p (n 5 48) 45% (30-59) 38% (24-52) 30% (19-47)
$CR2p (n 5 30) 31% (15-49) 32% (16-50) 24% (13-46)
OS indicates overall survival; PFS, progression-free survival; NRM, non-
relapse mortality; CR1, first complete remission; $CR2, equal to or
greater than second complete remission; CR1p, CR1 without platelet
recovery; and$CR2p, equal to or greater than second complete remis-
sion without platelet recovery.
Figure 1. Kaplan-Meier survival analysis. Cumulative incidence of (A)
overall survival (OS), (B) progression-free survival (PFS), and (C) nonre-
lapse mortality (NRM) by pretransplantation remission status. Data re-
flects preparative regimens used between July 1995 and December
2007. CR1, first complete remission; $CR2, equal to or greater than
second complete remission; CR1p, CR1 without platelet recovery;
and$CR2p, equal to or greater than second complete remission with-
out platelet recovery.
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plants in $CR2p (32%) (HR 5 1.7; P 5 .05) (Table
4 and Figure 1B). None of the additional prognostic
factors evaluated (listed previously had a significant
impact on OS or PFS in subgroup analyses.Prognostic Factors for NRM
A total of 82 patients died of nonrelapse causes in-
cluding graft failure (n 5 4), infection (n 5 13), pneu-
monia (n 5 8), acute GVHD (aGVHD) (n 5 12),
chronic GVHD (cGVHD) (n 5 21), organ failure
(n 5 11), veno-occlusive disease (n 5 2), secondary
malignancy (n 5 2), acute myocardial infarction (n 5
1), hemorrhage (n 5 1), and unknown causes while
in remission (n 5 7). In univariate analysis, platelet
recovery was the only significant predictor of NRM
at 36 months, which was significantly higher for
patients receiving transplants in CRp (28%; 95% CI
19-40) in comparison with patients receiving trans-
plants in CR (21%; 95% CI 17-27); (HR 5 1.7;
P 5 .03) (Table 3). Subgroup analyses showed that
the effect of platelet recovery was more pronounced
for patients in CR1 (HR 5 2.3, P 5 .01) than in
patients in $CR2 (HR 5 1.1, P 5 .90) (Table 3).
The estimated cumulative incidence of NRM at 36
months was 18% for patients in CR1; 30% for those
in CR1p; 27% for those in $CR2; and 24% for those
in $CR2p (Table 4 and Figure 1C).DISCUSSION
Many patients with AML/MDS achieve a morpho-
logic CR with\5% BM blasts, but fail to fully recover
hematopoiesis. In this report, we demonstrate that fail-
ure to achieve full platelet recovery (\100  109 plate-
lets/L) before allo-SCT is associated with worse
outcomes for patients with AML/MDS. The require-
ment for platelet recovery to define CR has been chal-
lenged. Some studies have proposed that achieving
$100 109 platelets/Lmaynot be as criticalwithnewer
AML therapies, and that outcomes following allo-SCT
would not be compromised [10,11]. Our results indicate
that patients fulfilling classical criteria for CR, including
a requirement for platelet recovery at the time of
transplantation, have better OS, PFS, and NRM rates
than those transplanted in CRp. We show that in the
allo-SCT setting, achieving a CRp is associated with
better outcomes than a lack of response to therapy
(data not shown), but worse outcomes compared with
achieving a CR. Unlike previous reports [10,11], our
study included patients in CR1 as well as patients in
disease status $CR2, making our conclusions broadly
applicable even to patients who are being considered
for allo-SCT in the salvage setting.
Although it is conceivable that in some patients
platelet recoverymay eventually be reachedwith longer
waiting periods before allo-SCT, in practice, such
delays before making therapeutic decisions are not fea-
sible and may cause adverse outcomes. We defined
CRp after a waiting period of at least 28 days in an at-
tempt tominimize selection bias, becausemost patients
likely to recover platelet counts will have achieved full
Biol Blood Marrow Transplant 17:1841-1845, 2011 1845Platelet Recovery Prior to allo-SCTrecovery by this time point. Use of the minimum
28-day time point to assess platelet recovery would
act to potentially improve the prognosis in the CRp
group, because some patients without disease may
have subsequently achieved later platelet recovery.
We acknowledge that a clear limitation of our
study is that patients in CRp are oftentimes excluded
from allo-SCT, because it may be a surrogate marker
of other morbid conditions, such as infections. This
may have caused a selection bias in the CRp patients
analyzed in this study that may have had a better per-
formance status than CRp patients who were excluded
from receiving allo-SCT. If such bias did occur here, it
could have contributed to better outcomes for the pa-
tients in CRp. This bias would actually strengthen our
conclusions that patients in CRp have significantly
worse outcomes compared with patients in CR. We
also recognize that our results should be cautiously in-
terpreted in the setting of MDS, given the small num-
ber of MDS patients included.
Worse outcomes were seen in CRp patients irre-
spective of the intensity of the preparative regimen
used. This fact would suggest that patients in CRp
be considered for novel therapies, including posttrans-
plantation maintenance [12].
In summary, our results indicate that in patients
with AML or MDS, achieving a CR, including
a platelet count of $100  109/L in PB, is associated
with improved survival and NRM compared with
CRp. Therefore, achievement of CR and CRp is
a valuable and efficient prognostic marker that needs
to be considered in the evaluation of novel transplan-
tation treatments.ACKNOWLEDGMENTS
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